atai Life Sciences to Participate in September Investor Conferences
ATAI(NASDAQ:ATAI) NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences.
'Texas Governor Signs Bill To Create Ibogaine Research Consortium, Aiming To Develop FDA-Approved Psychedelic Drug' - Marijuana Moment
ATAIColorado Governor Says Bill He Signed Allowing Psychedelic Convictions To Be Pardoned Marks A Step 'Towards A Fairer Future' - Marijuana Moment
ATAI'Doctor Seeking To Reschedule Psilocybin To Treat Dying Patients Demands DEA Update After Agency Agreed To Initiate Federal Review' - Marijuana Moment
ATAIatai And Beckley Merger Advances Strategic Vision For Psychedelic Drug Development With Deep CNS Expertise
ATAIEx-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
ATAIPsychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $10 Price Target
ATAIAtai Life Sciences Announces Topline Data From Part 2 Of Beckley Psytech's Phase 2a Study Of BPL-003 In Combination With SSRIs For Treatment-Resistant Depression
ATAIATAI Life Sciences Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $1.55M
ATAIatai Life Sciences Doses First Patient Dosed In Phase 2 Study Of EMP-01 For Social Anxiety Disorder; Topline Data anticipate In Q1 Of 2026
ATAIReported Earlier: 'Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy' - Marijuana Moment
ATAIHC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $10 Price Target
ATAIATAI Life Sciences Q4 EPS $(0.24) Misses $(0.15) Estimate
ATAI'Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research' - Marijuana Moment
ATAIatai Life Sciences Doses First Patient In Elumina Phase 2 Trial Of VLS-01 For Treatment-Resistant Depression
ATAIAtai Life Sciences Announced The Completion Of Patient Enrollment In The Eight-week, Double-blind, Core Stage Of The Global Phase 2B Clinical Trial Evaluating Bpl-003 (Mebufotenin Benzoate) In Patients With Treatment-resistant Depression (TRD)
ATAIHC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $10 Price Target
ATAIReported Earlier, atai Life Sciences Prices Public Offering Of 26.19M Common Shares At $2.10 Each, Raising $55M
ATAIATAI Life Sciences Commences Proposed Registered Underwritten Offering Of $55M Of Its Common Shares
ATAIHC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Lowers Price Target to $10
ATAICanaccord Genuity Maintains Buy on ATAI Life Sciences, Maintains $11 Price Target
ATAIHC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
ATAIGreat Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
ATAIThe season for psychedelics conferences is right around the corner. From very large and well-known events to small meets, this year’s remaining months are loaded with on-site and virtual discussions around the natural plant and synthetic medicines revolutionizing mental health.
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
ATAIThe world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.
Cathie Wood Finds Elon Musk's Comment On Psychedelics, Ketamine An 'Interesting Thesis' For This Stock
ATAIPopular stock picker Cathie Wood said on Sunday she finds Tesla Inc (NASDAQ: TSLA) CEO Elon Musk’s comments on the effectiveness of psychedelics and other plant-based substances as treatments for mental health-related issues an &ldquo
